Loading
A phase 3 trial testing BEBT-209 in HR-positive / HER2-negative breast cancer, now recruiting.
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy is a phase 3 interventional study registered as NCT06998108, led by BeBetter Med with Chinese Academy of Medical Sciences, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy. Planned enrolment is 330 participants (estimated). The study started in 2022-06-09 and primary completion is expected in 2025-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/